Relation between the antimicrobial susceptibility of clinical isolates of Pseudomonas aeruginosa from respiratory specimens and Antimicrobial Use Density (AUD) from 2005 through 2008

Internal Medicine

Volumn 49, Issue 14, 2010, Pages 1333-1340

  Fukushima, Yasutsugu ^a   Fukushima, Fumiya ^a   Kamiya, Kuniyoshi ^a   Hayashi, Yumeko ^a   Tatewaki, Masamitsu ^a   Yamada, Issei ^a   Hirata, Hirokuni ^a   Sugiyama, Kumiya ^a   Ishii, Yoshiki ^a   Fukuda, Takeshi ^a  

^a DOKKYO MEDICAL UNIVERSITY   (Japan)

Author keywords

Antimicrobial use density; Carbapenems; Fluoroquinolones; Fourth generation cephalosporins; Pseudomonas aeruginosa

Indexed keywords

AMIKACIN; ANTIINFECTIVE AGENT; BETA LACTAMASE; BIAPENEM; CARBAPENEM DERIVATIVE; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; GENTAMICIN; HABEKACIN; IMIPENEM; MEROPENEM; PIPERACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULPERAZON;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM ISOLATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; CROSS RESISTANCE; DRUG EFFICACY; DRUG USE; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PNEUMONIA; PSEUDOMONAS AERUGINOSA; RESPIRATORY TRACT INFECTION; SPUTUM CULTURE; TREND STUDY;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MICROBIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HOSPITALS, UNIVERSITY; HUMANS; MICROBIAL SENSITIVITY TESTS; PSEUDOMONAS AERUGINOSA; PSEUDOMONAS INFECTIONS;

EID: 77954974510     PISSN: 09182918     EISSN: 13497235     Source Type: Journal    
DOI: 10.2169/internalmedicine.49.3360     Document Type: Article

References (26)

1. Neuhauser MM, Weinstein RA, Rydman R, Danziger LH, Karam G, Quinn JP. Antibiotic resistance among gram-negative bacilli in US intensive care units: implications for fluoroquinolone use. JAMA 289: 885-888, 2003.
2. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 27: 887-892, 1999.
3. Gibb AP, Tribuddharat C, Moore RA, et al. Nosocomial outbreak of carbapenem-resistant Pseudomonas aeruginosa with a new blaIMP allele, blaIMP-7. Antimicrob Agents Chemother 46: 255-258, 2002.
4. Lolans K, Queenan AM, Bush K, Sahud A, Quinn JP. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne metallo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 49: 3538-3540, 2005.
5. Tsuji A, Kobayashi I, Oguri T, Inoue M, Yabuuchi E, Goto S. An epidemiological study of the susceptibility and frequency of multiple-drug resistant strains of Pseudomonas aeruginosa isolated at medical instituting nationwide in Japan. J Infect Chemother 11: 64-70, 2005.
6. Quinn JP, Dudek EJ, Divincenzo CA, Lucks DA, Lerner SA. Emergence of resistance to imipenem during therapy for Pseudomonas aeruginosa infections. J Infect Dis 154: 289-294, 1986.
7. Cao B, Wang H, Sun H, Zhu Y, Chen M. Risk factors and clinical outcomes of nosocomial multi-drug resistant Pseudomonas aeruginosa infections. J Hosp Infection 57: 112-118, 2004.
8. Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing, 17th informational supplement M100-S17. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. 7th ed. Clinical and Laboratory Standards Institute, Wayne, PA, 2007: M7-A7.
9. Arakawa Y, Shibata N, Shibayama K, et al. Convenient test for screening metalo-β-lactamase-producing gram-negative bacteria by using thiol compounds. J Clin Microbiol 38: 40-43, 2000.
10. The WHO Collaborating Centre for Drug Statistics Methodology. The ATC/DDD system 2009, http://www.whocc.no/atcddd/
11. Pai H, Kim J, Kim J, Lee JH, Choe KW, Gotoh N. Carbapenem resistance mechanisms in Pseudomonas aeruginosa clinical isolates. Antimicrob Agents Chemother 45: 480-484, 2001.
12. Li XZ, Nikaido H. Efflux-mediated drug resistance in bacteria. Drugs 64: 159-204, 2004.
13. Chen FJ, Lo HJ. Molecular mechanisms of fluoroquinolone resistance. J Microbiol Immunol Infect 36: 1-9, 2003.
14. Akasaka T, Tanaka M, Yamaguchi A, Sato K. Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrob Agents Chemother 45: 2263-2268, 2001.
15. Jana S, Deb JK. Molecular understanding of aminoglycoside action and resistance. Appl Microbiol Biotechnol 70: 140-150, 2006.
16. Livermore DM. Of Pseudomonas, porins, pumps and carbapenems. J Antimicrob Chemother 47: 247-250, 2001.
17. Walsh TR. The emergence and implications of metallo-betalactamases in Gram-negative bacteria. Clin Microbiol Infect 11 (Supple. 6): 2-9, 2005.
18. Quale J, Bratu S, Gupta J, Landman D. Interplay of efflux system, ampC, and oprD expression in carbapenem resistance of clinical isolates. Antimicrob Agents Chemother 50: 1633-1641, 2006.
19. Huang H, Hancock RE. Genetic definition of the substrate selectivity of outer membrane porin protein OprD of Pseudomonas aeruginosa. J Bacteriol 175: 7793-7800, 1993.
20. Kohler T, Michea-Hamzehpour M, Epp SF, Pechere JC. Carbapenem activities against Pseudomonas aeruginosa: Respective Contributions of OprD and Efflux Systems. Antimicrob Agents Chemother 43: 424-427, 1999.
21. Okamoto K, Gotoh N, Nishino T. Alterations of susceptibility of Pseudomonas aeruginosa by overproduction of multidrug efflux systems, MexAB-OprM, MexCD-OprJ, and MexXY-OprM to carbapenems: substrate specificities of the efflux systems. J Infect Chemother 8: 371-373, 2002.
22. Carmeli Y, Troillet N, Eliopoulos GM, Samore MH. Emergence of antibiotic-resistant Pseudomonas aeruginosa: comparison of risks associated with different antipseudomonal agents. Antimicrob Agents Chemother 43: 1379-1382, 1999.
23. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 104: 205-212, 2005.
24. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities and clinical outcomes. Clin Infect Dis 25: 230-239, 1997.
25. Miyazaki H. Change in antimicrobial susceptibility of Pseudomonas aeruginosa under restricted use of carbapenems. Kansenshogaku Zasshi 82: 6-13, 2008 (in Japanese).
26. Kim JY, Sohn JW, Park DW, Yoon YK, Kim YM, Kim MJ. Control of extended-spectrum ß-lactamase-producing Klebsiella pneumoniae using a computer-assisted management program to restrict third-generation cephalosporin use. J Antimicrob Chemother 62: 416-421, 2008.